Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T12:05:35.409Z.
Calculation as of: 2026-10-06T12:05:35.409Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 47b7d046e53ba400f53df530976eb059ace8f079140d97e9bcfa36b682aba175
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$453.70M
EBITDA Yield
N/A
TTM Avg
8.61%
3Y Avg
13.81%
5Y Avg
19.64%
Market Cap
$447.43M
EBITDA Yield
225.13%
TTM Avg
150.45%
3Y Avg
150.45%
5Y Avg
150.45%
Market Cap
$478.54M
EBITDA Yield
N/A
TTM Avg
25.96%
3Y Avg
19.61%
5Y Avg
19.61%
Market Cap
$416.68M
EBITDA Yield
N/A
TTM Avg
12.83%
3Y Avg
12.83%
5Y Avg
12.83%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Assembly Biosciences, Inc. (ASMB) | $450.64M | N/A | N/A | N/A | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $453.70M | N/A | 8.61% | 13.81% | 19.64% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $447.43M | 225.13% | 150.45% | 150.45% | 150.45% |
| NRC Health (NRC)vs › | $468.31M | 4.21% | 6.53% | 7.37% | 6.54% |
| Cerus Corporation (CERS)vs › | $471.57M | 0.01% | 0.01% | 0.01% | 0.01% |
| Editas Medicine, Inc. (EDIT)vs › | $428.16M | N/A | N/A | N/A | N/A |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | N/A | 25.96% | 19.61% | 19.61% |
| Arvinas, Inc. (ARVN)vs › | $481.33M | N/A | N/A | N/A | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $416.68M | N/A | 12.83% | 12.83% | 12.83% |
| Carlsmed, Inc. (CARL)vs › | $415.93M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
